Journal article
Fixed-dose combination therapy with daclatasvir, asunaprevir, and beclabuvir for noncirrhotic patients with HCV genotype 1 infection
F Poordad, W Sievert, L Mollison, M Bennett, E Tse, N Bräu, J Levin, T Sepe, SS Lee, P Angus, B Conway, S Pol, N Boyer, JP Bronowicki, I Jacobson, AJ Muir, KR Reddy, E Tam, G Ortiz-Lasanta, V De Lédinghen Show all
JAMA Journal of the American Medical Association | AMER MEDICAL ASSOC | Published : 2015
Abstract
IMPORTANCE: The antiviral activity of all-oral, ribavirin-free, direct-acting antiviral regimens requires evaluation in patients with chronic hepatitis C virus (HCV) infection. OBJECTIVE: To determine the rates of sustained virologic response (SVR) in patients receiving the 3-drug combination of daclatasvir (a pan-genotypic NS5A inhibitor), asunaprevir (an NS3 protease inhibitor), and beclabuvir (a nonnucleoside NS5B inhibitor). DESIGN, SETTING, AND PARTICIPANTS: This was an open-label, single-group, uncontrolled international study (UNITY-1) conducted at 66 sites in the United States, Canada, France, and Australia between December 2013 and August 2014. Patients without cirrhosis who were ei..
View full abstractGrants
Funding Acknowledgements
This study was funded by Bristol-Myers Squibb. Editorial support was provided by Andrew Street, PhD, of Articulate Science and was funded by Bristol-Myers Squibb.